Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases.
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Amicus Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FOLD's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: FOLD underperformed the US Biotechs industry which returned 25.7% over the past year.
Return vs Market: FOLD underperformed the US Market which returned 9.3% over the past year.
Price Volatility Vs. Market
How volatile is Amicus Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StIs Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) CEO Pay Justified?
1 month ago | Simply Wall StHow Does Amicus Therapeutics, Inc. (NASDAQ:FOLD) Affect Your Portfolio Volatility?
2 months ago | Simply Wall StAmicus Therapeutics, Inc. Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Is Amicus Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: FOLD ($12.68) is trading below our estimate of fair value ($55.08)
Significantly Below Fair Value: FOLD is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: FOLD is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: FOLD is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FOLD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FOLD is overvalued based on its PB Ratio (8.1x) compared to the US Biotechs industry average (3.7x).
How is Amicus Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FOLD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FOLD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FOLD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FOLD's revenue (36.5% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: FOLD's revenue (36.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FOLD is forecast to be unprofitable in 3 years.
How has Amicus Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FOLD is currently unprofitable.
Growing Profit Margin: FOLD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FOLD is unprofitable, and losses have increased over the past 5 years at a rate of -26% per year.
Accelerating Growth: Unable to compare FOLD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FOLD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: FOLD has a negative Return on Equity (-80.74%), as it is currently unprofitable.
How is Amicus Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: FOLD's short term assets ($407.9M) exceed its short term liabilities ($91.7M).
Long Term Liabilities: FOLD's short term assets ($407.9M) exceed its long term liabilities ($244.0M).
Debt to Equity History and Analysis
Debt Level: FOLD's debt to equity ratio (37.2%) is considered satisfactory.
Reducing Debt: FOLD's debt to equity ratio has increased from 12.9% to 37.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FOLD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if FOLD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Amicus Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FOLD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FOLD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FOLD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FOLD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FOLD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Crowley (52yo)
Mr. John F. Crowley has been the Chairman of Amicus Therapeutics, Inc. since February 2010 and has been its Chief Executive Officer since August 15, 2011. Mr. Crowley served as the Chief Executive Officer ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD9.85M) is above average for companies of similar size in the US market ($USD5.87M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
|Chairman & CEO||8.83yrs||US$9.85m||0.39% $12.7m|
|Chief Financial Officer||1.42yrs||US$2.48m||0.029% $931.8k|
|Chief Scientific Officer||4.92yrs||US$2.61m||0.14% $4.5m|
|Chief Legal Officer||4.33yrs||US$2.69m||0.020% $640.4k|
|Vice President of Finance||2yrs||no data||0.0022% $73.5k|
|Senior Vice President of Technical Operations||no data||no data||no data|
|Senior VP||4.83yrs||no data||no data|
|Senior Vice President of Global Marketing & Commercial Operations||5yrs||no data||no data|
|Senior Vice President of Business & Corporate Development||2.75yrs||no data||no data|
Experienced Management: FOLD's management team is considered experienced (4.8 years average tenure).
|Chairman & CEO||8.83yrs||US$9.85m||0.39% $12.7m|
|Independent Director||8yrs||US$278.83k||0.0034% $112.7k|
|Independent Director||1yr||US$433.25k||no data|
|Independent Director||14yrs||US$298.82k||0.0073% $237.9k|
|Independent Director||10.67yrs||US$296.33k||0.0073% $239.5k|
|Independent Director||8yrs||US$287.99k||0.059% $1.9m|
|Independent Director||4yrs||US$284.67k||0.0034% $112.7k|
|Lead Independent Director||1.75yrs||US$321.33k||0.0034% $112.7k|
|Independent Director||1.75yrs||US$285.80k||0.0015% $48.0k|
Experienced Board: FOLD's board of directors are considered experienced (6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.
Amicus Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Amicus Therapeutics, Inc.
- Ticker: FOLD
- Exchange: NasdaqGM
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.267b
- Shares outstanding: 257.66m
- Website: https://www.amicusrx.com
Number of Employees
- Amicus Therapeutics, Inc.
- 1 Cedar Brook Drive
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|FOLD||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||May 2007|
|AM6||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 2007|
|0HF9||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||May 2007|
|FOLD *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||May 2007|
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital, University of Pennsylvania, and GlaxoSmithKline. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/02 03:23|
|End of Day Share Price||2020/06/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.